Find Academic Supervisors

Scott BurrisView profile

Professor

• Public Health Law
• International Public Health Law
• Legal Epidemiology
• +7 more

Scott Burris is a Professor of Law at Temple Law School and Professor in Temple's School of Public Health, where he directs the Center for Public Health Law Research. He has been a faculty member at Temple since 1991 and is internationally recognized for his pioneering work in public health law, particularly in legal epidemiology, policy surveillance, and the intersection of law with HIV/AIDS policy and substance abuse. Professor Burris received his J.D. from Yale Law School and his B.A. from Washington University in St. Louis. His career began during the early days of the HIV/AIDS epidemic, where he served as an attorney at the American Civil Liberties Union, lobbying and litigating on behalf of people with HIV. He edited the first systematic legal analysis of HIV in the United States, "AIDS and the Law: A Guide for the Public" (Yale University Press, 1987). Burris's research focuses on how law influences public health and health behavior, with particular emphasis on developing theory and methods for effective local health governance. His work spans international public health law, legal epidemiology, policy surveillance, substance abuse policy, and housing law. He has made significant contributions to understanding the impact of law on HIV prevention, opioid overdose prevention, and pandemic response. His recent work increasingly examines methodological rigor in legal epidemiology, the application of artificial intelligence to legal analysis, and the relationship between housing law and health equity. His extensive publication record includes over 200 books, book chapters, articles, and reports. Recent publications demonstrate his continued leadership in advancing the science of legal epidemiology, with particular attention to methodology, policy surveillance systems, and innovative applications of technology to legal analysis. American Public Health Association Law Section Lifetime Achievement Award (2014) Jay Healey Health Law Professors award (2018) Professor Burris has served as a consultant to numerous international organizations including the United Nations Development Programme, the World Health Organization, and the United Nations Office on Drugs and Crime. He founded the Public Health Law Research Program for the Robert Wood Johnson Foundation in 2009, which has supported over 80 empirical studies of the impact of law on health. His research has been funded by major organizations including the Robert Wood Johnson Foundation, the Open Society Institute, the National Institutes of Health, the Bill and Melinda Gates Foundation, and the Centers for Disease Control and Prevention. He is the founder of Legal Science, LLC, a private company dedicated to improving access to legal information and supporting policy surveillance practice. He also serves as an advisor to several international institutions including the Tsinghua University AIDS Institute, the Shanghai Academy of Social Sciences Research Center for HIV/AIDS Public Policy, and the Program in Bioethics at Monash University. His work bridges academic research, practical application, and policy development in the field of public health law.

Danielle GermanView profile

Associate Professor

• Social determinants of health
• Harm reduction
• HIV/AIDS
• +12 more

Danielle German, PhD, MPH, is an Associate Professor in the Department of Health, Behavior and Society at the Johns Hopkins Bloomberg School of Public Health. She serves as Vice-Chair for Inclusion, Diversity, Anti-Racism, and Equity in her department and leads the LGBTQ Public Health Certificate Program. Her research is centered on the social and structural determinants of health among marginalized populations in Baltimore and across Maryland. PhD, Johns Hopkins Bloomberg School of Public Health, 2009 MPH, Emory University Rollins School of Public Health, 1998 BA, Rutgers University, 1996 Dr. German’s research focuses on drug use, harm reduction, HIV/AIDS, mental health, LGBTQ health, and social networks. She employs mixed methods—qualitative and quantitative—to explore how social stability, stigma, and structural factors influence health behavior and disease transmission. Her work emphasizes community-engaged and applied research, often in partnership with public health departments and community organizations. Her research portfolio includes major surveillance and implementation science projects such as BESURE (Baltimore’s CDC National HIV Behavioral Surveillance) and SEADS (Statewide Ethnographic Assessment of Drug Use and Services). Recent publications highlight trends in xylazine exposure, polysubstance use, HIV stigma, transgender health, and mental health among sexual minority women. Her work increasingly integrates social network interventions and telemedicine to improve access to care in underserved areas. Excellence in Teaching Award (2014–2017, 2019–2022) Ruth L. Kirchstein National Research Service Pre-Doctoral Training Award (2005–2009) Sir Arthur Newsholme Scholarship (2004–2008) Delta Omega Society (2009) Johns Hopkins SOURCE Service-Learning Community Fellow (2016) Dr. German has extensive experience mentoring students and training early-career researchers through federally funded programs. She has served as Principal Investigator and Co-PI on multiple grants focused on behavioral surveillance, harm reduction, and health equity. Her leadership in mixed methods research and LGBTQ health has positioned her as a key figure in public health research and education. She is actively involved in community-based research teams and collaborates widely across disciplines and institutions. She leads or contributes to several research labs and teams, including the Lighthouse Studies at Peer Point Center for Public Health and Human Rights, the Johns Hopkins Center for AIDS Research (JHU CFAR), and the Mixed Methods Research Training Program for the Health Sciences. These teams focus on interdisciplinary, community-responsive research to address structural barriers to health.

Lindsey J. LoeraView profile

Assistant Professor

• Addiction Medicine
• Pharmacotherapy
• Opioid Use Disorder
• +3 more

Lindsey J. Loera serves as Assistant Professor of Practice at The University of Texas at Austin College of Pharmacy and Associate Director of the Pharmacy Addictions Research & Medicine (PhARM) Program. A graduate of the same institution, she completed a two-year postgraduate research and teaching fellowship with the PhARM Program before assuming her current roles conducting Texas Targeted Opioid Response research and teaching pharmacotherapy and interprofessional collaboration courses. Education: Pharm.D. from University of Texas at Austin College of Pharmacy Two-year postgraduate research and teaching fellowship with PhARM Program Her research program centers on addiction medicine with specialized expertise in opioid use disorder interventions, naloxone/syringe accessibility, buprenorphine dispensing practices, and harm reduction strategies for people who inject drugs. She investigates critical public health issues including medication access barriers, wound care protocols, and mental health stigma reduction through interprofessional education. Her work bridges clinical pharmacy practice with community-based public health initiatives to address the opioid epidemic. Analysis of her 15 most recent publications (2020-2025) reveals consistent focus on community pharmacy-based solutions to substance use disorders, with dominant methodologies including audit studies, qualitative explorations, and policy analyses. Key thematic clusters include medication access disparities (particularly for naloxone and buprenorphine), innovative educational models for addiction medicine training, and operational challenges in harm reduction services. Scientific Awards: United States Public Health Service Excellence in Public Health Pharmacy Award (2019) American College of Clinical Pharmacy Research Fellowship Best Poster (2021) American Association of Colleges of Pharmacy Best Poster Finalist (2021) UT College of Pharmacy Mortar & Pestle Award (2020) Phi Delta Chi Lambda Chapter Alumni of the Year (2023) Phi Lambda Sigma Pharmacy Leadership Society Inductee (2018) Dr. Loera actively mentors Pharm.D. students and researchers, with her trainees consistently winning competitive awards including AMERSA Conference Travel Grants, Hazelden Betty Ford SIMS Program selections, and UT Center for Health IPE awards. She co-advises the Austin collegiate chapter of the American Association of Psychiatric Pharmacists and contributes to statewide initiatives including the Texas Opioid Training Initiative and TEACH OUD program. As Associate Director of the PhARM Program, she leads interdisciplinary teams developing evidence-based protocols for addiction treatment in community pharmacy settings. Her work integrates with mobile syringe services programs and public health departments to implement real-world solutions for substance use disorders across Texas.

Brendan SalonerView profile

Professor

• Health Policy
• Healthcare Reform
• Health Equity
• +4 more

Brendan Saloner, PhD, is a Bloomberg Professor of American Health at Johns Hopkins University, affiliated with the Bloomberg School of Public Health's Department of Health Policy and Management, the Berman Institute of Bioethics, and the Department of Mental Health. His research focuses on health equity, U.S. healthcare reform, and substance use disorder treatment. He holds a BA from UC Berkeley and a PhD in Health Policy from Harvard University, with a concentration in ethics. Dr. Saloner's work examines Medicaid cost-sharing policies, mental health treatment disparities, and opioid epidemic responses. His research has been featured in New England Journal of Medicine , Health Affairs , and major media outlets. He has received prestigious awards including the Alice S. Hersh Emerging Leader Award (2019) and fellowships from the Robert Wood Johnson Foundation and National Academy of Medicine. His recent studies address fentanyl's impact on older adults, opioid treatment in carceral settings, and harm reduction strategies. Key themes include policy innovations to reduce disparities in healthcare access and improving treatment retention for vulnerable populations. Education: BA (UC Berkeley), PhD (Harvard Health Policy) Awards: Alice S. Hersh Award (2019), RWJF Health & Society Scholar (2012-2014) Saloner collaborates with policymakers and clinicians to translate evidence into actionable solutions, emphasizing ethical frameworks in healthcare financing and delivery.

• HIV/AIDS epidemiology
• Injecting drug use
• Public health interventions
• +4 more

Don Des Jarlais is a Professor of Epidemiology at Columbia University's Mailman School of Public Health. He is also an adjunct faculty of psychiatry and preventive medicine at Icahn School of Medicine at Mount Sinai and a guest investigator at Rockefeller University in New York. His extensive research focuses on HIV/AIDS among people who inject drugs (PWID) and related public health interventions. Dr. Des Jarlais earned his BA in Behavioral Science from Rice University and his PhD in Social Psychology from the University of Michigan. His research spans HIV/AIDS epidemiology, hepatitis C, drug use patterns, and harm reduction strategies globally. He has conducted studies in numerous countries including Vietnam, Malaysia, and Iran, focusing on vulnerable populations and the intersection of drug use with infectious diseases. His recent publications reveal a strong focus on the impact of fentanyl on HIV transmission, hepatitis C elimination strategies, and the effects of the COVID-19 pandemic on PWID. His work consistently emphasizes the need for evidence-based harm reduction approaches and structural interventions to address health disparities among drug-using populations. The geographic scope of his research has expanded significantly, with recent studies in Asia complementing his longstanding work in New York City. New York State Department of Health Commissioner's award for promoting the health of persons who use drugs Dr. Des Jarlais serves as a consultant to major institutions including the U.S. Centers for Disease Control and Prevention, National Institute of Drug Abuse, National Academy of Sciences, and World Health Organization. He has held significant advisory roles, including formerly serving as a commissioner for the National Commission on AIDS, as a core group member of the UNAIDS Reference Group on HIV and Injecting Drug Use, and as a member of the President's Emergency Plan for AIDS Relief (PEPFAR) Scientific Advisory Board. His research consistently informs global policy on harm reduction and infectious disease prevention among PWID.

Joseph AmonView profile

Academic

• Human rights
• Right to health
• HIV
• +12 more

Joseph Amon is the Desmond M. Tutu Professor of Public Health and Human Rights and Distinguished Professor of the Practice in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health, where he also serves as Director of the Center for Public Health and Human Rights. Previously, he was Director of Global Health and Clinical Professor at the Drexel Dornsife School of Public Health. He holds visiting or adjunct appointments at SciencesPo, Princeton, Columbia, and Uniformed Services University of the Health Sciences. Education: PhD, Uniformed Services University of the Health Sciences (2002) MSPH, Tulane University School of Public Health and Tropical Medicine (1994) Dr. Amon's research focuses on the intersection of public health and human rights, particularly among marginalized populations. His work examines the impact of laws, policing, detention, and political determinants on health outcomes, with a strong emphasis on HIV, violence, migration, and drug policy. He has conducted extensive research on compulsory drug detention, police violence, and the criminalization of key populations. His recent publications reveal a consistent focus on human rights-based approaches to public health, with significant contributions in the areas of migration and trauma, global health policy, and structural determinants of health. His work combines empirical research with advocacy and policy engagement, often influencing national and international discourse. Scientific Awards: Centers for Disease Control and Prevention, Epidemic Intelligence Service, Mackel Award Department of Health and Human Services, Public Health Service, Unit Commendation Department of Health and Human Services, Secretary’s Award for Distinguished Service Dr. Amon is actively involved in academic leadership and mentorship. He was appointed Editor-in-Chief of Health and Human Rights in 2023, having served as Senior Editor from 2019 to 2023. He teaches courses such as "Human Rights in Public Health Practice" and "Prisons, Public Health, and Human Rights." His work is supported by collaborations across multiple countries and institutions, reflecting a strong international network in public health and human rights advocacy. Laboratories and Research Centers: Director, Center for Public Health and Human Rights, Johns Hopkins Bloomberg School of Public Health

Bruce SchackmanView profile

Professor

• Health Economics
• Substance Use Disorders
• HIV/AIDS Research
• +7 more

Bruce Schackman is a Professor in the School of Population Health Sciences at Weill Cornell Medical College. His research focuses on health economics, particularly in the areas of substance use disorders, HIV/AIDS, hepatitis C, and public health policy. He has extensive experience in cost-effectiveness analysis, simulation modeling, and implementation science, with a strong emphasis on harm reduction strategies for opioid use disorder and infectious disease management. Education: Ph.D. in Health Policy, Harvard University (2001) M.B.A. in Health Policy, Harvard University (1984) A.B. in Health Policy, Harvard College (1980) Research Interests: Schackman's work bridges economic evaluation and public health, examining the financial and clinical impacts of interventions for opioid overdose prevention, HIV treatment access, and hepatitis C care. His research often involves modeling health outcomes, assessing policy implications, and analyzing disparities in treatment access. Recent Publications: His 2025 and 2024 articles emphasize naloxone distribution equity, syringe service program adaptations post-pandemic, and economic evaluations of community-level opioid interventions. Topics include geospatial analysis, harm reduction, and health equity in overdose prevention strategies. Grants: Schackman leads or collaborates on major NIH-funded projects, including grants from NIDA, NICHD, and NIDDK, focusing on reversing overdose epidemics, improving access to long-acting injectables, and modeling the impact of HCV treatment in opioid programs. External Collaborations: He serves on scientific advisory boards, including at Simon Fraser University, and contributes to policy discussions on Medicaid, prescription drug monitoring, and integrated HIV/Substance Use Disorder care.

Karin FisherView profile

Lecturer

• Health services research
• Primary health care
• Public health issues
• +11 more

Dr. Karin Fisher is an Honorary Lecturer at the University of Newcastle's Department of Rural Health within the College of Health, Medicine and Wellbeing. With over 25 years of nursing experience, she transitioned to academia after completing her PhD at the University of New England, focusing on rural health, sexually transmitted infections, and health equity. Dr. Fisher holds a PhD from the University of New England. Her clinical background includes positions as Clinical Nurse Consultant at Hunter New England Health Service (1993-1997), Public Health Officer (1997-2007), Acting Director of Population Health & Planning (2002-2004), and Senior Research Officer (2008-2010) at Hunter New England Local Health Network. Dr. Fisher's research focuses on health services research, primary health care, public health issues, interprofessional collaboration, and health workforce issues with particular emphasis on equity perspectives. Her work explores Population Health issues, Sexually transmitted infections, Inequalities, Equity issues, Health service access, Rural workforce issues, and Difficult to access populations. She employs qualitative methodologies including Grounded theory and Mixed methods in her research. Her recent publications (2020-2024) demonstrate a strong focus on rural health workforce development, Indigenous health programs, telehealth service delivery, and interprofessional education. There's a clear trajectory in her work toward understanding how to improve health outcomes in rural and remote settings, with increasing attention to culturally safe practices for Aboriginal communities and innovative approaches to health professional education. Dr. Fisher has secured over $176,000 in research funding across 5 grants. Current projects include 'Out of sight, out of mind?' examining videoconferencing in rural healthcare education, exploration of rural palliative care models, and 'Yearning to yarn' focused on Aboriginal ways of knowing and learning. She currently supervises 2 students (one PhD and one Honours student) and has previously supervised 2 PhD students to completion. Her supervision focuses on topics related to Aboriginal health, nursing workforce, and graduate outcomes tracking. She works as part of a multidisciplinary team at the University of Newcastle that includes medicine, radiography, physiotherapy, nutrition and dietetics, pharmacy, occupational therapy, Indigenous health care, speech pathology and mental health professionals.

Julie BruneauView profile

Professor

• Addiction Medicine
• HIV/AIDS
• Hepatitis C
• +5 more

Dr. Julie Bruneau serves as a Full Professor in the Department of Family Medicine and Emergency Medicine at the University of Montreal's Faculty of Medicine. She holds dual appointments as a Regular Researcher at the CHUM Research Center (CRCHUM) within the Innovation Crossroads axis and as Director of the Quebec-Atlantic hub of the Canadian Research Initiative on Substance Misuse (CRISM). Her leadership extends to founding CHUM's Addiction Medicine Service—the largest such program in Canada—and holding the Canada Research Chair on Integrated Care for People Who Use Drugs. Her research program focuses on HIV and hepatitis C transmission dynamics among injection drug users , utilizing longitudinal cohort studies linked to geographic information systems to analyze environmental and individual risk factors. Additional work evaluates hepatitis C treatment accessibility for active drug users and develops integrated care models. Collaborations span epidemiology, clinical research, and basic science across Quebec, Canada, and international partners. Analysis of her publication trends reveals consistent focus on harm reduction policy implementation , evidence-based opioid crisis interventions , and health system adaptations for vulnerable populations . Recent work increasingly addresses pandemic-related service disruptions and spatial determinants of drug-related harms through multidisciplinary frameworks combining clinical care with population health approaches. Awards: Knight of the Order of Montreal (2022) Women of Distinction Awards - Public Services category (2021) Election to ACSS (2022) Dr. Bruneau leads the Quebec-Atlantic CRISM hub implementing national opioid use disorder guidelines adopted as Canada's standard of care since 2018. Her work established Montreal's first syringe distribution program through CACTUS Montréal and now drives North America's first city-scale hepatitis C elimination initiative. Current grants support integrated care models addressing stigma barriers in evidence-based service access. Her research infrastructure includes the Innovation Crossroads axis at CRCHUM, which fosters multidisciplinary collaboration across medicine, public health, and social sciences to address complex substance use challenges through learning hospital principles aligned with sustainable development goals.

David ForrestView profile

Associate Professor

• Medical Anthropology
• HIV Prevention
• Substance Use Disorders
• +1 more

Dr. David Forrest is an Associate Professor and Director of Graduate Studies in Anthropology at the University of Miami's College of Arts and Sciences, specializing in public health interventions for marginalized populations. His research develops innovative healthcare models for people who inject drugs (PWID), particularly through syringe services programs (SSPs). The CHARIOT project implements tele-harm reduction strategies to improve HIV prevention and substance use treatment access. Studies examine rapid antiretroviral initiation in SSP settings, barriers to PrEP adoption among opioid users, and systemic discrimination in healthcare delivery. Recent publications demonstrate successful viral suppression through SSP-based HIV care models. Current NIH-funded projects include: Clinical trials of comprehensive tele-harm reduction Studies on PrEP willingness in substance-using populations Implementation science for marginalized community healthcare

Beth MeyersonView profile

Professor

• Opioid Use Disorder
• Chronic Pain Management
• Aging Populations
• +5 more

Beth Meyerson, PhD, is a Professor at the University of Arizona College of Nursing and the Beverly Benson McCord Endowed Chair of Nursing. She serves as Policy Director for the Comprehensive Center for Pain & Addiction, focusing on aging populations at the intersection of chronic pain and opioid use disorder. Her work includes mentorship in the Harm Reduction Research Lab with national transdisciplinary collaborators and leading NIDA-funded studies like MPACT and AMP to improve treatment and clinical training for older adults. Roles: Professor, Policy Director, Endowed Chair, Lab Director Affiliations: University of Arizona College of Nursing, Comprehensive Center for Pain & Addiction, Harm Reduction Research Lab Her research addresses opioid treatment retention, trauma among providers, chronic pain disparities, and pharmacy-level harm reduction. Recent work explores aging-related challenges in methadone treatment, syringe access, and stigma in healthcare. She develops clinical decision support tools and training simulations for graduate nursing and medical practitioners. Recent publications (2025–2024) highlight topics in opioid use disorder, harm reduction policy, trauma-informed care, and disparities in chronic pain management. She leads national surveys, clinical trials, and community-based participatory research to bridge gaps in policy and practice. Scientific Award: Beverly Benson McCord Endowed Chair Students: Zhanette Coffee, PhD, MSN, APRN, FNP-C, CARN-AP Meyerson collaborates with transdisciplinary teams across eight universities and community organizations, prioritizing community-focused advocacy and provider resilience. She addresses systemic barriers to medication access and overdose prevention through pragmatic implementation studies in pharmacies.

Lucas G. HillView profile

Adjunct Associate Professor

• Substance Use Disorders
• Pharmaceutical Education
• Opioid Crisis Intervention
• +4 more

Lucas G. Hill, Pharm.D., FCCP serves as Adjunct Associate Professor of Pharmacy Practice at The University of Texas at Austin College of Pharmacy, maintaining a primary appointment as Associate Professor and Executive Director of the Program Evaluation and Research Unit at the University of Pittsburgh School of Pharmacy. His career bridges academic scholarship with community-engaged practice focused on substance use disorder interventions and pharmacy-based public health initiatives. Dr. Hill earned his Pharm.D. from the University of Missouri–Kansas City School of Pharmacy and completed a combined family medicine residency and faculty development fellowship at the University of Pittsburgh Medical Center. His educational background informs his dual expertise in clinical pharmacy practice and academic leadership. His research portfolio demonstrates sustained commitment to addressing the opioid crisis through multiple interconnected strands: improving naloxone accessibility, expanding buprenorphine dispensing in community pharmacies, developing harm reduction strategies, and implementing evidence-based educational programs. Notable projects include founding the Pharmacy Addictions Research and Medicine (PhARM) Program and directing Texas Targeted Opioid Response initiatives with over $34 million in funding. Dr. Hill's scholarly output reveals evolving focus from foundational work on naloxone accessibility (2018-2020) toward contemporary priorities including buprenorphine access barriers, xylazine contamination challenges, and structural approaches to harm reduction. His recent publications increasingly emphasize policy implementation, interdisciplinary collaboration, and community-centered solutions. American College of Clinical Pharmacy Fellow (2023) American College of Clinical Pharmacy New Educator Award (2021) American Pharmacists Association Generation Rx Award of Excellence (2020) UT College of Pharmacy 10 Most Impactful Faculty (2022, 2018) American Society of Health-System Pharmacists CEO's Award for Courageous Service (2018) As principal investigator for multiple opioid response grants totaling $38+ million from SAMHSA and other agencies, Dr. Hill has mentored numerous trainees including Claire Zagorski (WCAAR Bruce/Jones Fellowship) and Amber Tran (AMERSA Growing a Diverse Workforce Award). He serves on the Association for Multidisciplinary Education and Research in Substance Use and Addiction Board of Directors and the Journal of the American College of Clinical Pharmacy Editorial Board, while maintaining active media engagement through national interviews with CNN, NPR, and TIME. Dr. Hill directs the Texas Opioid Training Initiative and Texas Substance Use Symposium, creating collaborative platforms for policymakers, clinicians, and community stakeholders to address substance use challenges through evidence-based approaches.

Alexis M. RothView profile

Associate Professor

• Substance Use
• Reproductive/Sexual Health
• Community Engaged Research
• +7 more

Alexis M. Roth is an Associate Professor in the Department of Community Health and Prevention at Drexel University. Her work focuses on addressing health disparities through community-engaged research, particularly in substance use, infectious diseases, and women's health. She holds a PhD in health behavior from Indiana University, an MPH in international health and development from Tulane University, and a BA in Communication Studies and Spanish from Loyola Marymount University. Dr. Roth leads the Health Equity Advancement Lab (HEAL), established in 2018, which prioritizes co-creating sustainable public health solutions with marginalized communities. Her research explores intersections of gender, substance use, and health equity, emphasizing novel interventions for opioid overdose prevention and improving healthcare access for people who use drugs. Key areas include harm reduction strategies, syringe services programs, and digital health technologies for overdose response. Her work integrates mixed methods, combining quantitative epidemiological analyses with qualitative insights from participatory community engagement. Dr. Roth has authored over 40 peer-reviewed publications on drug use epidemiology, HIV/STI prevention, and overdose response systems. Her recent studies investigate wearable biosensor technologies for overdose detection, smartphone apps for overdose response networks, and ethical implementation of biometric tools in harm reduction settings. She collaborates with global institutions like the University of California, San Diego, and international organizations to advance evidence-based public health policies. Education: PhD in Health Behavior, Indiana University MPH in International Health and Development, Tulane University BA in Communication Studies and Spanish, Loyola Marymount University Her research is funded by grants from NIH, CDC, and foundations addressing addiction and infectious disease control. Dr. Roth advises graduate students in public health and mentors early-career researchers in community-based participatory research methods.

• Public Health
• Substance Use and Addiction
• HIV Prevention
• +6 more

Dr. Lauretta Grau is a Research Scientist at the Yale School of Public Health , affiliated with the Department of Epidemiology of Microbial Diseases . Her work bridges clinical psychology and public health, focusing on behavioral and epidemiological aspects of substance use, HIV/hepatitis prevention, and harm reduction strategies. Dr. Grau has led innovative research projects, including multisite evaluations of syringe services programs and mixed-methods studies on the HIV Care Continuum. She specializes in technology-based interventions for smoking cessation and opioid use disorder treatment, alongside qualitative analyses of healthcare delivery systems and medication-assisted treatment access. Her recent publications examine overdose prevention, geospatial drug trends, and treatment accessibility challenges. These works span disciplines like Public Health , Substance Abuse , and Health Equity , with subfields including Opioid Policy , Telehealth Implementation , and Global Health Interventions .

• Epidemiology
• Public Health
• Substance Use Disorders
• +3 more

Roman Ivasiy is an Associate Research Scientist at Yale School of Medicine's AIDS department. He holds an MD from Danylo Halytskiy Lviv National Medical University (2014) and an MPH in Epidemiology from Georgia State University (2021, Fulbright-sponsored). His research focuses on substance use disorders, HIV/AIDS prevention, and LGBTQ+ health disparities, with emphasis on global health policy and conflict-related disruptions. He collaborates extensively with institutions in Ukraine, Kyrgyzstan, and Kazakhstan. Research highlights include evaluating opioid agonist therapies (OAT) scale-up, analyzing treatment retention during the COVID-19 pandemic, and studying provider stigma impacts in Ukraine. He contributed to policy recommendations during Russia's invasion of Ukraine, emphasizing continuity of OAT services for PWID. Awards: 2025 CIRA Pilot Projects in HIV Research Awardee Key Collaborators: Frederick Altice, Lynn Madden, Amanda Liberman Funding: Multiple NIH-funded studies on opioid use disorder and HIV/HCV comorbidities His work spans 3 continents, with recent studies published in International Journal of Drug Policy , AIDS , and Contemporary Clinical Trials . He advocates for evidence-based responses to health crises in conflict zones and marginalized populations.